ClinicalTrials.gg
CompletedNCT02542657Updated Nov 2, 2026Results posted

Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma

A Phase 1/2 interventional study of Clarithromycin and Dexamethasone in Myeloma, sponsored by Joseph Tuscano. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Joseph Tuscano · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 2, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 502 studies in Neoplasms, Plasma Cell with a site in United States — 26 open to participants now, 43 under way, 2 of them phase 3. Neoplasms, Plasma Cell · United States.

Enrollment
195th of 386
32 · median 33
Started
2015
with 7 others
Phase 1/2
57 of 502
4 open now
Registered
418th of 502
by date

Among the 502 studies in Neoplasms, Plasma Cell with a site in United States, this one is the 195th largest by enrollment of the 386 interventional ones that give a count, is one of 8 that started in 2015, is one of 57 in phase 1/2, and was the 418th registered.

Neoplasms, Plasma Cell

710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.

Browse Neoplasms, Plasma Cell studies →

Open to participants now

26 of the 502 studies in Neoplasms, Plasma Cell with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 502 studies in Neoplasms, Plasma Cell with a site in United States, or all of them as a file.
02

Study summary

This phase I/II trial studies the side effects and best dose of clarithromycin when given together with ixazomib citrate, pomalidomide, and dexamethasone and to see how well it works in treating patients with multiple myeloma that has not responded to previous treatment. Biological therapies, such as clarithromycin, pomalidomide, and dexamethasone, use substances made from living organisms that may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving clarithromycin with ixazomib citrate, pomalidomide and dexamethasone may be a better treatment for patients with multiple myeloma.

Read the detailed description

PRIMARY OBJECTIVES:

I. To establish the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) for PiC-D therapy (pomalidomide, ixazomib [ixazomib citrate], clarithromycin, and dexamethasone) in patients with multiple myeloma who are bortezomib and lenalidomide refractory. (Phase I) II. To determine the complete response (CR) and stringent CR (sCR) rate for PiC-D therapy in patients with multiple myeloma who are bortezomib and lenalidomide refractory. (Phase II)

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability of PiC-D therapy. (Phase I) II. To characterize the pharmacokinetics (PK) in plasma of oral ixazomib in combination with pomalidomide, clarithromycin and dexamethasone. (Phase I) III. To assess preliminary evidence of clinical activity. (Phase I) IV. To assess the effects of PiC-D therapy on quality of life (QOL). (Phase I)

VI. To evaluate the safety of PiC-D therapy. (Phase II) VII. To determine the overall response rate (ORR) (ORR; CR, sCR, partial response, and very good partial response. (Phase II) VIII. To determine the clinical benefit rate (CBR) (CBR; minimal response + ORR). (Phase II) IX. To determine the disease control rate (DCR) (DCR; stable disease + CBR). (Phase II) X. To determine the duration of response (DOR) in patients achieving a partial response or better. (Phase II) XI. To determine the time to next treatment (TNT). (Phase II) XII. To determine progression free survival (PFS) and overall survival (OS). (Phase II)

OUTLINE: This is a phase I, dose-escalation study of clarithromycin followed by a phase II study.

Patients receive pomalidomide orally (PO) once daily (QD) on days 1-21; ixazomib citrate PO on days 1, 8, and 15; clarithromycin PO twice daily (BID) on days 15-21 of course 1 and days 1-21 and courses 2-6; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE THERAPY:

Patients receive pomalidomide, ixazomib citrate, and dexamethasone as above and receive clarithromycin PO BID or QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 2-3 months for up to 3 years.

03

Conditions studied

  • Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written consent
  • Patients must have a confirmed diagnosis of a multiple myeloma
  • Submission of original biopsy for review and verification by hematopathologist at local institution
  • Patients must have according to International Myeloma Working Group (IMWG) criteria; measurable disease includes at least one of the following criteria:

    • Serum M-protein >= 1.0 g/dL, and/or
    • Urine M-protein >= 200 mg/24 hours, and/or
    • Involved serum free light chain >= 10 mg/dL (>= 100 mg/L) AND an abnormal serum free light chain ratio, and/or
    • Baseline marrow burden or myeloma of at least 30%
  • Disease that has progressed during or within 6 months of coming off therapy with bortezomib and lenalidomide (either sequentially or concurrent); progressive disease is defined as any of the following:

    • An increase of >= 25% from lowest response value in any of the following:

      • Serum M-protein (absolute increase must be >= 0.5 g/dL) AND/OR
      • Urine M-protein (absolute increase must be >= 200 mg/24 hours) AND/OR
      • For patients without a measurable serum or urine M-protein but measurable disease by serum free light chain testing: Difference between the involved and uninvolved serum free light chain level (absolute increase must be >= 10 mg/dL) AND/OR
      • For patients without a measurable serum or urine M-component or serum free light chain level: % marrow involvement with myeloma (absolute increase must be >= 10%) AND/OR
    • Definite development of new bone lesions or extramedullary plasmacytomas or definite increase in the size of existing bone lesions or extramedullary plasmacytomas AND/OR
    • Hypercalcemia (corrected serum calcium > 11.5 mg/dL) attributable to myeloma (e.g. not due to omitted doses of bisphosphonate)
  • of greater than 3 months
  • (ECOG) performance status and/or other performance status 0, 1, or 2
  • Disease free of prior for > 5 years with exception of patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
  • (ANC) >= 1,000/mm\^3 and
  • count >= 50,000/mm\^3; note: platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment
  • Total =\< 2.0 × the (ULN)
  • (ALT) and aspartate aminotransferase (AST) =\< 2.5 × ULN
  • Calculated >= 30 mL/min
  • Female patients who:

    • Are for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of , agree to practice two effective methods of , at the same time, from the time of signing the form through 90 days after the last dose of study drug, OR
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
  • Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:

    • Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)

Exclusion criteria

Exclusion Criteria:

  • Female patients who are lactating or have a positive serum pregnancy test during the screening period
  • Treatment with clarithromycin, anti-myeloma therapy including agents or plasmapheresis within 30 days prior to treatment in this study
  • Failure to have fully recovered (i.e., =\< grade 1 toxicity or to patient's clinical baseline) from the reversible effects of prior chemotherapy
  • Major surgery within 14 days before enrollment
  • Radiotherapy within 14 days before enrollment
  • Central nervous system involvement
  • Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
  • Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
  • Systemic treatment within 14 days before the first dose of study drugs, or concurrent use, with any of the following:

    • Strong inhibitors of cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2)
    • Strong inhibitors of family cytochrome P450 family 3, subfamily A (3A)
    • Strong cytochrome 3A polypeptide 4 inducers
  • Known ongoing or active systemic infection, active or C virus infection
  • Patients with (HIV) infection may be eligible provided they meet the following:

    • No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness
    • Cluster of differentiation (CD)4+ cells nadirs > 350/mm\^3
    • Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load \< 50 copies/mm\^3; please note: HIV+ patients who enroll on this study may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450; adverse events in HIV+ patients will be reported separately
  • Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
  • Known allergy to any of the study medications, their analogues, or in the various formulations of any agent
  • Previous allergic reaction to an immunomodulatory drug (IMiD)
  • Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drugs including difficulty swallowing
  • Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
  • Previous treatment with ixazomib or pomalidomide
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Treatment (PiC-D therapy)

    Patients receive pomalidomide PO QD on days 1-21; ixazomib citrate PO on days 1, 8, and 15; clarithromycin PO BID on days 15-21 of course 1 and days 1-21 of courses 2-6; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients receive pomalidomide, ixazomib citrate, and dexamethasone as above and receive clarithromycin PO BID or QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: Clarithromycin · Drug: Dexamethasone · Drug: Ixazomib Citrate · Drug: Pomalidomide

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) (Phase I)

    The MTD is defined as the highest dose tested in which fewer than 33% of patients experience a dose limiting toxicity and at least 6 patients have been treated at that dose. The MTD will be the recommended Phase 2 dose, provided that other safety considerations are acceptable. Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

    Time frame: About 14 months.

  2. Complete Response (CR) and Stringent CR (Phase 2)

    Defined by the International Myeloma Working Group (IMWG) criteria. omplete response (CR) = Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow. Stringent complete response (sCR) = CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence\>

    Time frame: Up to about 7 years

Secondary outcomes

  1. Safety and Tolerability of PiC-D Therapy (Phase 1)

    Proportion of patients experiencing dose limiting toxciity (DLT).

    Time frame: Up to about 14 months

  2. Preliminary Evidence of Clinical Activity (Phase 1).

    SD (stable disease), VGPR (very good partial response), sCR (stringent complete response), overall response rate (ORR), CBR (clinical benefit rate), and DCR (disease control rate).

    Time frame: Up to 3 years

  3. Quality of Life (Phase 1)

    Cancer Therapy Satisfaction Questionnaire and EORTC QLQ-MY20 score.

    Time frame: Up to 2 years

  4. Safety (Phase 2)

    Proportion of patients experiencing treatment-emergent adverse events, graded according to CTCAE v4.03.

    Time frame: Up to about 2.5 years

  5. Overall Response Rate (ORR) (Phase 2)

    ORR = PR+VGPR+CR. Overall response rate (ORR) includes Partial Response (PR) + Very Good Partial Response (VGPR) + Complete Response (CR). Response will be assessed per the International Myeloma Working Group (IMWG) Response Criteria

    Time frame: Up to about 7 years

  6. Clinical Benefit Rate (CBR) (Phase 2)

    CBR = Number of participants with Minimal Response (MR) or better, defined as sCR (Stringent Complete Response) + CR (Complete Response) + VGPR (Very Good Partial Response) + PR (Partial Response) + MR (Minimal Response).

    Time frame: Up to 3 years

  7. Disease Control Rate (DCR) (Phase 2)

    Disease control rate (DCR) = stable disease (SD) + overall response rate (ORR)

    Time frame: Up to about 7 years

  8. Duration of Response (DOR) (Phase 2)

    DOR = Partial response (PR) or better. PR defined per IMWG as ≥ 50% reduction of serum M-protein and reduction in 24 h urinary M-protein by ≥ 90% or to \< 200 smg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥ 50% reduction in plasma cells is required in place of the M-protein, provided baseline bone marrow plasma cell percentage was ≥ 30% In addition to the above listed criteria, if present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

    Time frame: Up to about 7 years

  9. Progression Free Survival (PFS) (Phase 2)

    Median progression free survival (PFS) - Median time from initiation of study intervention to progressive disease (PD) per IMWG criteria.

    Time frame: Up to 3 years

  10. Overall Survival (OS) (Phase 2)

    Median time from initiation of study intervention to death from any cause

    Time frame: Up to about 6 years

  11. Quality of Life (QoL) (Phase 2)

    Cancer Therapy Satisfaction Questionnaire (CTSQ-16) - Perceived worth of therapy, taken at screening and at end of treatment.

    Time frame: Baseline and end of treatment (up to 3 years).

  12. Phamacokinetic Parameters of Ixazomib Citrate

    Data not collected

    Time frame: at 0.5, 1, 1.5, 2, 4, 8, and 24 hours after ixazomib citrate administration on days 1 and 8.

07

Results

Posted Nov 2, 2026

Participant flow

Participant flow — Overall Study
MilestonePhase 1: Dose Level 1Phase 1: Dose Level -1Phase 2: Treatment (PiC-D Therapy) MTD Expansion
Started6026
Completed6026
Not completed000

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) (Phase I)

The MTD is defined as the highest dose tested in which fewer than 33% of patients experience a dose limiting toxicity and at least 6 patients have been treated at that dose. The MTD will be the recommended Phase 2 dose, provided that other safety considerations are acceptable. Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Time frame:
About 14 months.
Reported as:
Number · mg
Maximum Tolerated Dose (MTD) (Phase I)
mgPhase 1: Treatment (PiC-D Therapy) Dose Escalation
Maximum Tolerated Dose (MTD) (Phase I)250
PrimaryComplete Response (CR) and Stringent CR (Phase 2)

Defined by the International Myeloma Working Group (IMWG) criteria. omplete response (CR) = Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow. Stringent complete response (sCR) = CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence\>

Time frame:
Up to about 7 years
Reported as:
Count of participants · Participants
Complete Response (CR) and Stringent CR (Phase 2)
ParticipantsPhase 2: Treatment (PiC-D Therapy) MTD Expansion
Complete Response (CR) and Stringent CR (Phase 2)6
SecondarySafety and Tolerability of PiC-D Therapy (Phase 1)

Proportion of patients experiencing dose limiting toxciity (DLT).

Time frame:
Up to about 14 months
Reported as:
Count of participants · Participants
Safety and Tolerability of PiC-D Therapy (Phase 1)
ParticipantsPhase 1: Treatment (PiC-D Therapy) Dose Escalation
Safety and Tolerability of PiC-D Therapy (Phase 1)1
SecondaryPreliminary Evidence of Clinical Activity (Phase 1).

SD (stable disease), VGPR (very good partial response), sCR (stringent complete response), overall response rate (ORR), CBR (clinical benefit rate), and DCR (disease control rate).

Time frame:
Up to 3 years
Reported as:
Number · participants
Preliminary Evidence of Clinical Activity (Phase 1).
participantsPhase 1: Treatment (PiC-D Therapy) Dose Escalation
SD2
VGPR2
sCR1
ORR3
CBR3
DCR5
SecondaryQuality of Life (Phase 1)

Cancer Therapy Satisfaction Questionnaire and EORTC QLQ-MY20 score.

Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondarySafety (Phase 2)

Proportion of patients experiencing treatment-emergent adverse events, graded according to CTCAE v4.03.

Time frame:
Up to about 2.5 years
Reported as:
Count of participants · Participants
Safety (Phase 2)
ParticipantsPhase 2: Treatment (PiC-D Therapy) MTD Expansion
Safety (Phase 2)28
SecondaryOverall Response Rate (ORR) (Phase 2)

ORR = PR+VGPR+CR. Overall response rate (ORR) includes Partial Response (PR) + Very Good Partial Response (VGPR) + Complete Response (CR). Response will be assessed per the International Myeloma Working Group (IMWG) Response Criteria

Time frame:
Up to about 7 years
Reported as:
Number · participants
Overall Response Rate (ORR) (Phase 2)
participantsPhase 2: Treatment (PiC-D Therapy) MTD Expansion
Overall Response Rate (ORR) (Phase 2)21
SecondaryClinical Benefit Rate (CBR) (Phase 2)

CBR = Number of participants with Minimal Response (MR) or better, defined as sCR (Stringent Complete Response) + CR (Complete Response) + VGPR (Very Good Partial Response) + PR (Partial Response) + MR (Minimal Response).

Time frame:
Up to 3 years
Reported as:
Number · participants
Clinical Benefit Rate (CBR) (Phase 2)
participantsPhase 2: Treatment (PiC-D Therapy) MTD Expansion
Clinical Benefit Rate (CBR) (Phase 2)21
SecondaryDisease Control Rate (DCR) (Phase 2)

Disease control rate (DCR) = stable disease (SD) + overall response rate (ORR)

Time frame:
Up to about 7 years
Reported as:
Count of participants · Participants
Disease Control Rate (DCR) (Phase 2)
ParticipantsPhase 2: Treatment (PiC-D Therapy) MTD Expansion
Disease Control Rate (DCR) (Phase 2)28
SecondaryDuration of Response (DOR) (Phase 2)

DOR = Partial response (PR) or better. PR defined per IMWG as ≥ 50% reduction of serum M-protein and reduction in 24 h urinary M-protein by ≥ 90% or to \< 200 smg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥ 50% reduction in plasma cells is required in place of the M-protein, provided baseline bone marrow plasma cell percentage was ≥ 30% In addition to the above listed criteria, if present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

Time frame:
Up to about 7 years
Reported as:
Median · months
Duration of Response (DOR) (Phase 2)
monthsPhase 2: Treatment (PiC-D Therapy) MTD Expansion
Duration of Response (DOR) (Phase 2)19.8 (12.4 to NA)
SecondaryProgression Free Survival (PFS) (Phase 2)

Median progression free survival (PFS) - Median time from initiation of study intervention to progressive disease (PD) per IMWG criteria.

Time frame:
Up to 3 years
Reported as:
Median · months
Progression Free Survival (PFS) (Phase 2)
monthsPhase 2: Treatment (PiC-D Therapy) MTD Expansion
Progression Free Survival (PFS) (Phase 2)22.2 (13.3 to NA)
SecondaryOverall Survival (OS) (Phase 2)

Median time from initiation of study intervention to death from any cause

Time frame:
Up to about 6 years
Reported as:
Median · months
Overall Survival (OS) (Phase 2)
monthsPhase 2: Treatment (PiC-D Therapy) MTD Expansion
Overall Survival (OS) (Phase 2)NA (22.1 to NA)
SecondaryQuality of Life (QoL) (Phase 2)

Cancer Therapy Satisfaction Questionnaire (CTSQ-16) - Perceived worth of therapy, taken at screening and at end of treatment.

Time frame:
Baseline and end of treatment (up to 3 years).
Reported as:
Number · percentage of participants
Quality of Life (QoL) (Phase 2)
percentage of participantsQoL Item: Worth Taking Even With Side Effects, ScreeningQoL Iiem: Worth Taking Even With Side Effects, End of TreatmentQoL Item: Overall Worthwhileness - ScreeningQoL Item: Overall Worthwhileness - End of Treatment
Never6.205.90
Rarely60016.7
Sometimes12.533.311.850.0
Most of the Time12.533.329.40
Always62.533.352.933.3
SecondaryPhamacokinetic Parameters of Ixazomib Citrate

Data not collected

Time frame:
at 0.5, 1, 1.5, 2, 4, 8, and 24 hours after ixazomib citrate administration on days 1 and 8.

No measurements were reported for this outcome.

Adverse events

Collected over From date of first study treatment until date of off treatment: up to 2.5 years for serious adverse events and other (not including serious) adverse events; and up to about 7 years for all-cause mortality.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (PiC-D Therapy)0/32 (0%)6/32 (18.8%)32/32 (100%)
Most frequent serious events
Most frequent serious events
EventTreatment (PiC-D Therapy)
Cerebrovascular AccidentVascular disorders1/32
Colonic perforationGastrointestinal disorders1/32
InfluenzaInfections and infestations1/32
Neoplasm, other-disease progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/32
OsteomyelitisEar and labyrinth disorders1/32
Upper GI hemorrhageGastrointestinal disorders1/32
Most frequent other events
Showing 10 of 76
Most frequent other events
EventTreatment (PiC-D Therapy)
FatigueGeneral disorders20/32
ConstipationGastrointestinal disorders15/32
NauseaGastrointestinal disorders14/32
InsomniaPsychiatric disorders12/32
DiarrheaGastrointestinal disorders10/32
HypertensionVascular disorders10/32
CoughRespiratory, thoracic and mediastinal disorders9/32
PainGeneral disorders9/32
Upper respiratory infectionInfections and infestations9/32
DyspneaRespiratory, thoracic and mediastinal disorders8/32

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase 1: Treatment (PiC-D Therapy) Dose EscalationPhase 2: Treatment (PiC-D Therapy) MTD ExpansionTotal
<=18 years000
Between 18 and 65 years167
>=65 years52025
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Treatment (PiC-D Therapy) Dose EscalationPhase 2: Treatment (PiC-D Therapy) MTD ExpansionTotal
Female3710
Male31922
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Treatment (PiC-D Therapy) Dose EscalationPhase 2: Treatment (PiC-D Therapy) MTD ExpansionTotal
Hispanic or Latino246
Not Hispanic or Latino42226
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Phase 1: Treatment (PiC-D Therapy) Dose EscalationPhase 2: Treatment (PiC-D Therapy) MTD ExpansionTotal
United States62632
08

Study locations

3 sites
  • University of California San Diego
    La Jolla, California 92093-0960, United States
  • University of California Irvine
    Orange, California 92868, United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
09

References and documents

Publications

  • Rosenberg AS, Maverakis E, Costello C, Brem EA, Wieduwilt MJ, Luxardi G, Kaesberg P, Abedi K, Herbert S, Tuscano J. Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis. Blood Neoplasia. 2025 Jan 16;2(3):100067. doi: 10.1016/j.bneo.2025.100067. eCollection 2025 Aug. PubMed 40948663 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2015 to primary completion in Dec 2022, 85 months.

Results were first posted in Nov 2026, 3 years 10 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Aug 2025 → Dec 2022 and completion Dec 2025 → Nov 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2015
First posted
Sep 7, 2015
StartActual
Oct 22, 2015
Primary completionActual
Dec 7, 2022was Aug 2025
CompletionActual
Nov 11, 2024was Dec 2025
Results first posted
Nov 2, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 2, 2026
Results
Results posted
posted Nov 2, 2026
Primary completion
Aug 2025→Dec 7, 2022 (actual)
Nov 2, 2026
Study completion
Dec 2025→Nov 11, 2024 (actual)
Nov 2, 2026
Enrollment
30→32
Nov 2, 2026
Primary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedMaximum Tolerated Dose (MTD) (Phase I)Time frame: About 14 months.
  • AddedComplete Response (CR) and Stringent CR (Phase 2)Time frame: Up to about 7 years
  • RemovedMTD of clarithromycin when given in combination with ixazomib citrate, pomalidomide, and dexamethasone assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)Time frame: 28 days
Nov 2, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40948663 ↗
Nov 2, 2026
Secondary outcomes
12 added, 4 removed
What changed in the outcomes
  • AddedSafety and Tolerability of PiC-D Therapy (Phase 1)Time frame: Up to about 14 months
  • AddedPreliminary Evidence of Clinical Activity (Phase 1).Time frame: Up to 3 years
  • AddedQuality of Life (Phase 1)Time frame: Up to 2 years
  • AddedSafety (Phase 2)Time frame: Up to about 2.5 years
  • AddedOverall Response Rate (ORR) (Phase 2)Time frame: Up to about 7 years
  • AddedClinical Benefit Rate (CBR) (Phase 2)Time frame: Up to 3 years
  • AddedDisease Control Rate (DCR) (Phase 2)Time frame: Up to about 7 years
  • AddedDuration of Response (DOR) (Phase 2)Time frame: Up to about 7 years
  • AddedProgression Free Survival (PFS) (Phase 2)Time frame: Up to 3 years
  • AddedOverall Survival (OS) (Phase 2)Time frame: Up to about 6 years
  • AddedQuality of Life (QoL) (Phase 2)Time frame: Baseline and end of treatment (up to 3 years).
  • AddedPhamacokinetic Parameters of Ixazomib CitrateTime frame: at 0.5, 1, 1.5, 2, 4, 8, and 24 hours after ixazomib citrate administration on days 1 and 8.
  • RemovedClinical best responseTime frame: Up to 3 years
  • Removedother outcomeChange in immune modulation with the addition of clarithromycin (Phase II)Time frame: Up to 3 years
  • Removedother outcomeChange in immune modulation without the addition of clarithromycin (Phase II)Time frame: Baseline to up to 3 years
  • Removedother outcomePharmacokinetic parameters of ixazomib citrate (Individual and mean plasma ixazomib concentration data)Time frame: At 0.5, 1, 1.5, 2, 4, 8, and 24 hours after ixazomib citrate administration on days 1 and 8
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Active, not recruiting→Completed
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40948663 ↗
    Primary completion Aug 2025→Dec 7, 2022 (now actual)
    Study completion Dec 2025→Nov 11, 2024 (now actual)
    Enrollment 30→32
    Primary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedMaximum Tolerated Dose (MTD) (Phase I)Time frame: About 14 months.
    • AddedComplete Response (CR) and Stringent CR (Phase 2)Time frame: Up to about 7 years
    • RemovedMTD of clarithromycin when given in combination with ixazomib citrate, pomalidomide, and dexamethasone assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)Time frame: 28 days
    Secondary outcomes 12 added, 4 removed
    What changed in the outcomes
    • AddedSafety and Tolerability of PiC-D Therapy (Phase 1)Time frame: Up to about 14 months
    • AddedPreliminary Evidence of Clinical Activity (Phase 1).Time frame: Up to 3 years
    • AddedQuality of Life (Phase 1)Time frame: Up to 2 years
    • AddedSafety (Phase 2)Time frame: Up to about 2.5 years
    • AddedOverall Response Rate (ORR) (Phase 2)Time frame: Up to about 7 years
    • AddedClinical Benefit Rate (CBR) (Phase 2)Time frame: Up to 3 years
    • AddedDisease Control Rate (DCR) (Phase 2)Time frame: Up to about 7 years
    • AddedDuration of Response (DOR) (Phase 2)Time frame: Up to about 7 years
    • AddedProgression Free Survival (PFS) (Phase 2)Time frame: Up to 3 years
    • AddedOverall Survival (OS) (Phase 2)Time frame: Up to about 6 years
    • AddedQuality of Life (QoL) (Phase 2)Time frame: Baseline and end of treatment (up to 3 years).
    • AddedPhamacokinetic Parameters of Ixazomib CitrateTime frame: at 0.5, 1, 1.5, 2, 4, 8, and 24 hours after ixazomib citrate administration on days 1 and 8.
    • RemovedClinical best responseTime frame: Up to 3 years
    • Removedother outcomeChange in immune modulation with the addition of clarithromycin (Phase II)Time frame: Up to 3 years
    • Removedother outcomeChange in immune modulation without the addition of clarithromycin (Phase II)Time frame: Baseline to up to 3 years
    • Removedother outcomePharmacokinetic parameters of ixazomib citrate (Individual and mean plasma ixazomib concentration data)Time frame: At 0.5, 1, 1.5, 2, 4, 8, and 24 hours after ixazomib citrate administration on days 1 and 8
    + 6 other changes: identifiers, verification date, oversight details, description, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02542657
Lead sponsor
Joseph Tuscano
Collaborators
Takeda, Celgene
Responsible party
Joseph Tuscano (Principal Investigator, University of California, Davis) — Sponsor-investigator
First posted
Sep 7, 2015
Start date
Oct 22, 2015
Primary completion
Dec 7, 2022
Completion
Nov 11, 2024
Results posted
Nov 2, 2026
Last update
Nov 2, 2026

Study contacts

Joseph Tuscano
principal investigator · University of California, Davis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixazomib

Start the discussion